3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Sarcoma
1
Conditions
Gliosarcoma
3
Glioblastoma
3
Neoplasms
2
Glioma
2
Brain Neoplasms
2
Recurrence
1
Interventions
Temozolomide
88
Bevacizumab
49
Radiotherapy
36
Irinotecan
22
Magnetic Resonance Spectroscopy
21
Surgical Procedures, Operative
17
Carboplatin
17
Carmustine
15
Radiation
13
Nivolumab
11
IL13-PE38
8
Erlotinib Hydrochloride
8
Thalidomide
7
Radiotherapy, Intensity-Modulated
7
Lomustine
7
Imatinib Mesylate
7
Everolimus
7
Aminolevulinic Acid
7
sargramostim
6
Topotecan
6
O(6)-benzylguanine
6
Cyclophosphamide
6
Chemotherapy, Adjuvant
6
vandetanib
5
temsirolimus
5
fluorodopa F 18
5
Vincristine
5
Surveys and Questionnaires
5
Radiosurgery
5
Flucytosine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Glioma
×
rindopepimut
×
Clear all
NCT00458601
2018-01-16
ACT III
Celldex Therapeutics
Phase 2
Completed
82 enrolled
NCT00626015
2016-01-21
ZAP IT
Duke University
Phase 1
Completed
16 enrolled